A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The clinical-economic expediency of using omalizumab in asthmatic children has not been previously studied in Russia.Objective: Our aim was to evaluate the clinical and econom...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Paediatrician Publishers, LLC
2016-11-01
|
| Series: | Pediatričeskaâ Farmakologiâ |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/1440 |